The Distribution of the HIV Protease Inhibitor, Ritonavir, to the Brain, Cerebrospinal Fluid, and Choroid Plexuses of the Guinea Pig
Open Access
- 1 March 2004
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 308 (3) , 912-920
- https://doi.org/10.1124/jpet.103.060210
Abstract
Anti-human immunodeficiency virus (HIV) drug penetration into the brain and cerebrospinal fluid (CSF) is necessary to tackle HIV within the CNS. This study examines movement of [3H]ritonavir across the guinea pig blood-brain and blood-CSF barriers and accumulation within the brain, CSF, and choroid plexus. Ritonavir is a protease inhibitor, used in combination therapy (often as a pharmacoenhancer) to treat HIV. Drug interactions at brain barrier efflux systems may influence the CNS penetration of anti-viral drugs, thus the influence of additional protease inhibitors, nucleoside reverse transcriptase inhibitors, and non-nucleoside reverse transcriptase inhibitors on [3H]ritonavir CNS distribution was explored. Additionally, the involvement of transporters on [3H]ritonavir passage across the brain barriers was assessed. Results from in situ brain perfusions and capillary depletion analysis demonstrated that [3H]ritonavir uptake into the guinea pig brain was considerable (6.6 ± 0.7 ml/100 g at 30 min, vascular space corrected), although a proportion of drug remained trapped in the cerebral capillaries and did not reach the brain parenchyma. CSF uptake was more limited (2.2 ± 0.4 ml/100 g at 30 min), but choroid plexus uptake was abundant (176.7 ± 46.3 ml/100 g at 30 min). [3H]Ritonavir brain and CSF uptake was unaffected by neither inhibitors of organic anion transport (probenecid and digoxin) or P-glycoprotein (progesterone), nor by any additional anti-HIV drugs, indicating that brain barrier efflux systems do not significantly limit brain or CSF [3H]ritonavir accumulation in this model. [3H]Ritonavir uptake into the perfused choroid plexus was significantly reduced by nevirapine and abacavir, additional perfusion studies, and isolated incubated choroid plexus experiments were carried out in an attempt to further characterize the transporter involved.This publication has 45 references indexed in Scilit:
- Cerebrospinal Fluid HIV RNA and Drug Levels With Combination Ritonavir and SaquinavirJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- Detection of HIV‐1 DNA in Microglia/ Macrophages, Astrocytes and Neurons Isolated from Brain Tissue with HIV‐1 Encephalitis by Laser Capture MicrodissectionBrain Pathology, 2003
- The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjectsBritish Journal of Clinical Pharmacology, 2002
- Choroid Plexus Transporters for Drugs and Other XenobioticsJournal of Drug Targeting, 2002
- Transport of Human Immunodeficiency Virus Type 1 Pseudoviruses across the Blood-Brain Barrier: Role of Envelope Proteins and Adsorptive EndocytosisJournal of Virology, 2001
- RitonavirClinical Pharmacokinetics, 1998
- Localization of HIV‐1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistryAnnals of Neurology, 1996
- Passage of a δ‐Opioid Receptor Selective Enkephalin, [d‐Penicillamine2,5]Enkephalin, Across the Blood‐Brain and the Blood‐Cerebrospinal Fluid BarriersJournal of Neurochemistry, 1996
- Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.Journal of Clinical Investigation, 1995
- Capillary Depletion Method for Quantification of Blood–Brain Barrier Transport of Circulating Peptides and Plasma ProteinsJournal of Neurochemistry, 1990